

## Research

# Helicobacter pylori and precancerous conditions of the stomach: the frequency of infection in a cross-sectional study of 79 consecutive patients with chronic antral gastritis in Yaoundé, Cameroon

Firmin Ankouane<sup>1,8</sup>, Dominique Noah Noah<sup>2</sup>, Félicien Ntoné Enyime<sup>1</sup>, Carole Menzy Ndjollé<sup>3</sup>, Roger Nsenga Djapa<sup>1</sup>, Bernadette Ngo Nonga<sup>4</sup>, Oudou Njoya<sup>1</sup>, Elie Claude Ndjitoyap Ndam<sup>1</sup>

<sup>1</sup>Department of internal medicine and specialties, Faculty of medicine and biomedical sciences, University of Yaounde 1, Cameroon, <sup>2</sup>Department of clinical sciences, Faculty of medicine and pharmaceutical sciences, University of Douala, Cameroon, <sup>3</sup>Department of morphological sciences, anatomy and pathology, Faculty of medicine and biomedical sciences, University of Yaounde 1, Cameroon, <sup>4</sup>Department of surgery and specialties, Faculty of medicine and biomedical sciences, University of Yaounde 1, Cameroon

<sup>8</sup>Corresponding author: Firmin Ankouane, Department of internal medicine and specialties, Faculty of medicine and biomedical sciences, University of Yaounde 1, Cameroon

Key words: Helicobacter pylori, gastritis, intestinal metaplasia, precancerous conditions of the stomach, Cameroon

Received: 04/12/2014 - Accepted: 15/01/2015 - Published: 20/01/2015

### Abstract

**Introduction:** The study aimed at determining the different types of precancerous conditions of the stomach and searches the frequency of *Helicobacter pylori* in these lesions in patients with chronic antral gastritis in Yaounde, Cameroon. **Methods:** Five gastric biopsies were performed during upper gastrointestinal endoscopy for pathology and fixed in formol 10% before being coated in paraffin. Both the modified Giemsa and Periodic acid of Shift – Alkaline blue stains were used for the histological diagnosis of *Helicobacter pylori* infection. Hematoxylyn and eosin stain was used to determine the activity of gastritis, atrophic gastritis and intestinal metaplasia in accordance to the Sydney's classification of gastritis. Data were analysed using both the Epi info 6.04 and Excel 2007 softwares. Means and their standard deviations, medians and their interquartiles (IQR) were calculated. Proportions were established for qualitative variables and chi square analysis done in this study with a p value set at 0.05. **Results:** Seventy-nine patients with chronic antral gastritis were enrolled, of which 43 (54.4%) were male, median age: 43 years (range from 21 to 70 years). The rate of atrophic gastritis was 74.7% (59/79). The activity of atrophic gastritis was mild in 47.5% (28/59) of cases, moderate in 47.5% (28/59) and severe in 5% (5/59). Intestinal metaplasia and follicular gastritis were present in 6.3% (5/79), and 10.1% (8/79), respectively. Concerning *Helicobacter pylori* infection, 71.2% (42/59) of patients with atrophic gastritis tested positive against 28.8% (17/59) who tested negative ( $p = 0.00003$ ). Helicobacter pylori infection was related to the severity of gastric atrophy ( $p = 0.0001$ ). Among patients with intestinal metaplasia and follicular gastritis, the proportion of those who tested positive for *Helicobacter pylori* infection was 80% (4/5), and 75% (6/8), respectively. There were no significant differences in the occurrence of atrophic gastritis according to age groups ( $p = 0.908$ ). **Conclusion:** This study concludes that atrophic gastritis, which is most often caused by *Helicobacter pylori*, is the most frequent precancerous condition of stomach in Cameroon. Routine gastric sampling for pathologic analysis is mandatory for effective diagnosis and surveillance of *Helicobacter pylori* infection and precancerous conditions of the stomach.

**Pan African Medical Journal. 2015; 20:52 doi:10.11604/pamj.2015.20.52.5887**

This article is available online at: <http://www.panafrican-med-journal.com/content/article/20/52/full/>

© Firmin Ankouane et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Introduction

Chronic gastritis, especially that associated to *Helicobacter pylori* (*H. pylori*) predisposes to the intestinal form of gastric carcinoma [1-3]. The histological sequence which leads to the occurrence of gastric cancer has been elucidated [1]. With regards to the pathogenesis of the intestinal types of carcinoma, it is known that atrophic gastritis is the early step, followed by intestinal metaplasia, then dysplasia before the appearance of gastric carcinoma [2-5]. Atrophic gastritis and intestinal metaplasia are thus considered early markers of gastric cancer, being precancerous conditions [6]. Pathologic analysis of gastric specimens is fundamental in diagnosing chronic gastritis, as it helps classify lesions according to the degree of severity, which vary from superficial gastritis to severe atrophic gastritis [7]. Conventional endoscopy is inadequate in establishing the extent of microscopic lesions.

*H. pylori* is highly endemic in Cameroon [8]. Prospective studies carried out using serological data have clearly established that *H. pylori* constantly leads to gastritis and is a major risk factor of both the intestinal and diffuse types of gastric cancer [9]. Furthermore, *H. pylori* has been considered by the World Health Organization (WHO) as a carcinogen, as it accounts for most gastric cancers. Its eradication will mostly be beneficial in preventing gastric cancer before the appearance of precancerous conditions [10].

However, despite the aforementioned facts, no endoscopic algorithm for the evaluation of gastritis exists in our country. Pathologic analysis of gastric specimens is not routinely practiced. Conventional endoscopy coupled to *H. pylori* detection using the rapid urease test are the only routinely practiced investigations. In the absence of pathology and chromoendoscopy, establishing the existence of precancerous conditions of the stomach in our daily practice is scarce [11].

We thus determined, through a cross-sectional study, the prevalence of atrophic gastritis, intestinal metaplasia and follicular gastritis in our environment, and also determine the frequency of *H. pylori* in these lesions in patient with chronic antral gastritis using the Sydney classification to evaluate gastritis.

## Methods

It was a cross-sectional study carried out from January 2013 to February 2014, both at the Yaounde Central Hospital and the University Hospital Center. Sampling was consecutive, and all patients aged between 20 and 70 years old, referred for an upper gastrointestinal (GI) endoscopy, and who had the histological diagnosis of antral gastritis were enrolled. Patients with upper GI bleeding, with active bleeding during endoscopy, those on antibiotics or antisecretory drugs within the month preceding the endoscopy and patients with a past history of gastrectomy were excluded from the study. Five gastric biopsies were sampled during upper GI endoscopy for pathologic analysis and diagnosis of *H. pylori* infection, in accordance to the Sydney's classification of gastritis [12, 13], these biopsies included: 2 at the level of the antrum (2cm from the pylorus), 1 at the angularis and 2 in the body of the stomach. Formol 10% was used to fix the specimens before being coated with paraffin.

Standard staining techniques including hematoxylin & Eosin, Giemsa, Periodic Acid Shift (PAS) and alkaline blue were used. Hematoxylin & Eosin helped describe morphology, PAS and alkaline

blue described lesions of malpighian intestinal metaplasia, while Giemsa was used to identify *H. pylori* in the bottom of gastric crypts and at the apical poles of cells. Conclusions of an upper GI endoscopy were not made known to the pathologist. The following parameters were clearly precised in the pathologist report: chronic infiltrate, atrophic gastritis (graded as absent, mild, moderate and severe), intestinal metaplasia (described as absent or present), follicular gastritis (described as absent or present), and the presence of *H. pylori* infection was ascertained when the bacterium was identified in histological sections. In this study, only the antral predominance of gastritis was taken into account.

**Ethical consideration:** the study was approved by the Ethics Committee of the Faculty of Medicine and Biomedical Sciences of University of Yaounde 1, Cameroon and signed informed consent was obtained from all included participants.

**Statistical analysis:** data was analysed using both the Epi info 6.04 and Excel 2007 softwares. For quantitative variables, means and their standard deviations, medians and their interquartiles (IQR) were calculated. Proportions were established for qualitative variables. To examine the relationship between two discrete variables, we used Pearson's  $\chi^2$  test. Yates correction and Fischer's exact test were used for small sample sizes, with a p value set at 0.05

## Results

### Demographics characteristics and prevalence of precancerous conditions of the stomach

A total of 870 upper GI endoscopies were performed during the period of the study. Seventy-nine patients with chronic antral gastritis met our inclusion's criteria. The study population comprised 43 males (54.4%) and 36 females (45.6%) with a sex ratio of 1.2. The median age was 43 years old (range from 21 to 70 years).

**Table 1** represents the prevalence of precancerous conditions of the stomach in 79 patients with chronic antral gastritis, according to the Sydney's classification of gastritis. The prevalence of atrophic gastritis among them was 74.7% (59/79). Considering the degree of activity of gastritis, it was mild in 47.5% (28/59) of patients with atrophic gastritis, moderate in 47.5% (28/59), and severe in 5% (5/59). The prevalence of intestinal metaplasia and follicular gastritis were 6.3% (5/79), and 10.1% (8/79), respectively.

### Helicobacter pylori infection and precancerous conditions of the stomach in chronic antral gastritis

The relation between *H. pylori* infection and the occurrence of precancerous conditions of the stomach is portrayed on **Table 2**. As depicted by the table, 71.2% (42/59) of patients with atrophic gastritis were *H. pylori* positive against 28.8% (17/59) who were *H. pylori* negative ( $p = 0.00003$ ). The severity of atrophic gastritis was related to the presence of *H. pylori* infection ( $p = 0.0001$ ). The proportions of patients who were *H. pylori* positive among patients with intestinal metaplasia and follicular gastritis were 80% (4/5), and 75% (6/8), respectively.

### Prevalence of precancerous conditions of the stomach with respect to age and gender in chronic antral gastritis

The distribution of precancerous conditions of the stomach with respect to gender and age is depicted on **Table 3**. Age did not significantly influence the occurrence of atrophic gastritis ( $p =$

0.908). The prevalence values of atrophic gastritis at age's ranges of 20-40 years, 41-60 years, and above 60 years were 45.8%, 33.9%, and 20.3%, respectively. Concerning the degree of severity of atrophic gastritis, mild and moderate degrees of atrophic gastritis regressed with age, while severe atrophic gastritis predominated among those aged between 41 – 60 years old accounting for 66.7% (2/3) of cases. There were no significant differences in prevalence values of atrophic gastritis between males and females (49.2%, and 50.8%, respectively;  $p = 0.272$ ). The prevalence values of intestinal metaplasia at age's ranges of 20-40 years, 41-60 years, and above 60 years were 20%, 40%, and 40%, respectively. The prevalence values of intestinal metaplasia in males and females were 20%, and 80%, respectively. There were no significant differences in prevalence values of follicular gastritis according to age. It was more frequent among male patients than among female patients (62.5%, and 37.5 %, respectively).

## Discussion

In Cameroon, the incidence, prevalence and mortality of gastric cancer has not been clearly established, although gastric cancer has been reported to be the second most common gastrointestinal malignancy [14, 15]. In Europe, notably in France where data exists, gastric cancer is the fourth most common gastrointestinal cancer, with a poor prognosis, having a 5-years survival rate of about 25% [16 – 18]. The histological sequence leading to gastric cancer has been established, and passes through precancerous conditions [1, 4]. It successively passes through atrophic gastritis, intestinal metaplasia, dysplasia before carcinoma [1 – 3].

In this study, we found a high rate of atrophic gastritis (74.7%) in patients with chronic antral gastritis, but intestinal metaplasia (6.3%) and follicular gastritis (10.1%) were rare. This finding is similar to those found in low risk groups for gastric cancer. Paradoxically, it is different from the findings of a study in Cote d'Ivoire, a country whose settings are similar to ours and where, these lesions were very frequent [19]. It is known that the distribution of precancerous conditions of the stomach varies with respect to countries [17, 18, 20]. In very high risk groups like Japan and China, and certain high risk groups (blacks and Hispanics) in the United States of America, the rate of precancerous conditions of the stomach is generally very high [20 – 23]. Discrepancies in the diagnosis of precancerous conditions of the stomach may also be related to the site of gastric biopsy. The angularis, for instance, harbours more precancerous conditions than the body and the antrum [24]. In this study, analysis was limited to the antrum this may explain our results and may limit the value of our findings. Also, the relatively small sample of this study constitutes a limit.

*H. pylori* infection is responsible for 80% of atrophic gastritis and is related to the development of precancerous conditions of the stomach and their progression to carcinoma [3, 5, 9, 19, 24]. The association between *H. pylori* infection and atrophic gastritis or intestinal metaplasia increases the risk of gastric cancer to five - six-fold [3, 6, 18, 25]. *H. pylori* infection is both related to the severity of histological lesions and the activity of chronic antral gastritis [3, 9, 25, 26]. Results of this study indicated that *H. Pylori* infection is frequent in precancerous conditions of the stomach and it's associated to the severity of histological lesions of the stomach (71.2% in atrophic gastritis and 80% in intestinal metaplasia).

In western countries, the majority of precancerous conditions of the stomach and gastric cancers are diagnosed beyond 75 years [16 – 18]. In this study, we found a high rate of precancerous conditions of the stomach before the age of 60 years. This early onset of the

development of *H. pylori* related gastric cancer has been clearly established in many studies carried out in other developing countries [5, 8, 19, 20]. Intestinal metaplasia was more frequent among female patients (80%), though this could not be accounted for.

## Conclusion

Atrophic gastritis often caused by *H. pylori*, is the most frequent precancerous condition of the stomach in Cameroon. Routine gastric sampling for pathologic analysis is mandatory for effective diagnosis and surveillance of *H. pylori* infection and precancerous conditions of the stomach. The progression of precancerous conditions to gastric cancer which mortality remains high will be halted by the eradication of *H. Pylori* infection.

## Competing interests

The authors declare no competing interest.

## Authors' contributions

FA: study conception and Design, data analysis; DNN: performed endoscopy; CMN: performed histological exams; FNE: statistical analyses, drafting of the manuscript; RND: participated in the study design and helped to draft the manuscript; BNN: study conception, drafting of the manuscript; ON: statistical analyses, data interpretation and supervision; ECNN: study conception, drafting of the manuscript, supervision. All authors have read and approved the final manuscript.

## Acknowledgments

The authors wish to acknowledge the support of Dr Pefura Yone Eric Walter for data analysis.

## Tables

**Table 1:** prevalence of precancerous conditions of the stomach among patients with histological proven chronic antral gastritis in Yaounde

**Table 2:** comparison between Helicobacter pylori positive patients and Helicobacter pylori negative patients with precancerous conditions of the stomach among patients with histological proven chronic antral gastritis in Yaounde

**Table 3:** prevalence of precancerous conditions of the stomach with respect to age and gender among patients with histological proven chronic antral gastritis in Yaounde

## References

1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: First american cancer society award lecture on cancer epidemiology and prevention. *Cancer Res.*1992; 52(24):6735-40. **PubMed | Google Scholar**

2. Byrd JC, Yan P, Sternberg L, Yunker CK, Scheiman JM, Bresalier RS. Aberrant expression of gland-type gastric mucin in the surface epithelium of *Helicobacter pylori*-infected patients. *Gastroenterology*. 1997; 113(2):455-64. **PubMed | Google Scholar**
3. Kuipers EJ. Review article: exploring the link between *Helicobacter pylori* and gastric cancer. *Aliment Pharmacol Ther*. 1999; 13 (Suppl 1):3-11. **PubMed | Google Scholar**
4. Owen DA. Gastritis and carditis. *Mod Pathol*. 2003 Apr; 16(4):325-41. **PubMed | Google Scholar**
5. Schmidt HM, Ha DM, Taylor EF, Kovach Z, Goh KL, Fock KM, Barrett JH, Forman D, Mitchell H. Variation in human genetic polymorphisms, their association with *H pylori* acquisition and gastric cancer in a multi-ethnic country. *J Gastroenterol Hepatol*. 2011; 26(12):1725-32. **PubMed | Google Scholar**
6. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. *Helicobacter pylori* infection and the development of gastric cancer. *N Engl J Med*. 2001; 345(11):784-9. **PubMed | Google Scholar**
7. Mainguet P, Moulinier B. Endoscopic methods in the exploration of gastritis. *Acta Endoscopica*. 1982 ; 12(2):449-458. **PubMed | Google Scholar**
8. Ankouane Andoulo F, Noah Noah D, Tagni-Sartre M, Ndjitoyap Ndam EC, Ngu Blackett K. Epidémiologie de l'infection à *Helicobacter pylori* à Yaoundé: de la particularité à l'énigme Africaine. *The Pan African Medical Journal*. 2013; 16:115. **PubMed | Google Scholar**
9. Leodolter A, Ebert MP, Peitz U. Prevalence of *H pylori* associated high risk gastritis for development of gastric cancer in patients with normal endoscopic findings. *World J Gastroenterol*. 2006; 12(34): 5509- 12. **PubMed | Google Scholar**
10. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon ATR, Dixon MF. Changing patterns of *Helicobacter pylori* gastritis in long-standing acid suppression. *Helicobacter*. 2000;5(4):206-14. **PubMed | Google Scholar**
11. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A et al. Management of precancerous conditions and Lesions of the stomach (MAPS): guidelines from the European society of Gastrointestinal Endoscopy, European *Helicobacter* Study Group (EHSg), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). *Endoscopy*. 2012; 44(1):74-94. **PubMed | Google Scholar**
12. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney System, International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol*. 1996; 20(10):1161-81. **PubMed | Google Scholar**
13. El-Zimaity HM. Accurate diagnosis of *Helicobacter pylori* with biopsy. *Gastroenterol Clin North Am*. 2000; 29(4):863-9. **PubMed | Google Scholar**
14. Ankouane Andoulo F, Ngo Nonga B, Noah Noah D, Kowo M, Dang Babagna I, Tayou C et al. Etiologies and risk factors of acute upper gastrointestinal hemorrhage: analysis of 613 cases in Yaounde. *Port Harcourt Medical Journal*. 2013; 7(3):175-182. **PubMed | Google Scholar**
15. Ngo Nonga B , Pisoh TC , Ankouane AF, Mouafo Tambo F, Essomba A, Takongmo S, Sosso MA. Emergency total gastrectomy for massive haemorrhage in a low income country. *Port Harcourt Medical Journal*. 2012; 6(2):136-141. **PubMed | Google Scholar**
16. Institut national du cancer (INCa). La situation du cancer en France en 2012. <http://www.ladocumentationfrancaise.fr/var/storage/rapportspublics/134000042/0000.pdf>. Accessed 12 April 2014. **PubMed | Google Scholar**
17. Institut de veille sanitaire (InVS). Projections de l'incidence et de la mortalité par cancer en France en 2010. [Http://www.invs.sante.fr /applications/ cancers /projections2010 /default.htm](http://www.invs.sante.fr/applications/cancers/projections2010/default.htm). Accessed 12 April 2014. **PubMed | Google Scholar**
18. Vaillant É. Prévention et dépistage du cancer de l'estomac. Association Française de Formation Médicale Continue en Hépatogastro-Entérologie 2014. Journées Nationales de Formation Médicale Continue en Hépatogastro-Entérologie. Post'U 2014:179-184. <http://www.fmcgastro.org/textes-postus/postu-2014/prevention-et-depistage-du-cancer-de-lestomac/> Accessed 20 July 2014. **PubMed | Google Scholar**
19. Attia KA, N'dri Yoman T, Diomande MI, Mahassadi A, Sogodogo I, Bathaïx YF, Kissi H, Serme K, Sawadogo A, Manlan Kassi L. Aspects cliniques, endoscopiques et histologiques des gastrites chroniques à *Helicobacter pylori* en côte d'ivoire : étude de 102 patients . *Bull Soc Pathol Exot*. 2001;94(1):57-70. **PubMed | Google Scholar**
20. Rafik Jmaa, Belgacem Aïssaoui, Lamia Golli, Ali Jmaa, jaouad Al Qaddi, Aïda Ben Slama, Sonia Ziadi, Salem Ajmi . Les particularités de la gastrite chronique à *Helicobacter pylori* au centre ouest de la Tunisie. *Tunis Med*. 2010; 88(3):147-151. **PubMed | Google Scholar**
21. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. *Helicobacter*. 2001; 6(4):294-9. **PubMed | Google Scholar**
22. You WC, Zhang L, Gail MH, Li JY. Precancerous lesions in two countries of China with contrasting gastric cancer risk. *Int J Epidemiol*. 1998; 27(6):945-8. **PubMed | Google Scholar**
23. Tailley NJ, Fox KM, Moayyedi P. Gastric cancer consensus conference recommends *Helicobacter pylori* screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. *Am J Gastroenterol*. 2008; 103(3):510-4. **PubMed | Google Scholar**
24. Zhang C, Yamada N, Wu YL, Wen M, Matsuhisa T, Matsukura N. *Helicobacter pylori* infection, glandular atrophy and intestinal metaplasia in superficial gastritis, gastric erosion, erosive gastritis, gastric ulcer and early gastric cancer. *World J Gastroenterol*. 2005; 11(6):791-6. **PubMed | Google Scholar**

25. Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and *Helicobacter pylori* and its sequelae. *Clin Gastroenterol*. 2001; 32(3):196-202. **PubMed** | **Google Scholar**
26. Rudelli A, Vialette G, Brazier F, Seurat PL, Capron D, Dupas JL.[*Helicobacter pylori* and gastro-duodenal lesions in 547 young patients with upper gastrointestinal symptoms]. *Gastroenterol Clin Biol*. 1996; 20(4):379-393. **PubMed** | **Google Scholar**